Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
复制标题
DOI：
10.1002/mds.21741
复制
发表时间：
2007-12-01
影响因子：
8.6
通讯作者：
Schapira, Anthony Hn.
中科院分区：
文献类型：
--
作者：
Giladi, Nir;Boroojerdi, Babak;Schapira, Anthony Hn.
罗替戈汀是一种新的非麦角类多巴胺受体激动剂，用于透皮给药系统。本研究探讨罗替戈汀透皮贴剂治疗早期帕金森病的疗效和安全性。患者（n = 561）被随机分配至罗替戈汀、罗匹尼罗或安慰剂组。滴定期长达13周，罗匹尼罗和罗替戈汀的最小剂量维持期分别为24周和33周。主要终点是统一帕金森病评定量表第II部分和第III部分评分降低至少20%的患者比例。罗替戈汀组的应答率显著高于安慰剂组（52%比30%，P < 0.0001）。罗替戈汀透皮给药剂量
Rotigotine is a new, non-ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine, ropinirole, or placebo. The titration period was up to 13 weeks, and there was a minimum dose-maintenance period of 24 weeks for ropinirole and 33 weeks for rotigotine. The primary endpoint was the proportion of patients with a minimum of 20% decrease in the combined Unified Parkinson's Disease Rating Scale Part II and Part III scores. The responder rate in the rotigotine group was significantly higher than in the placebo group (52% vs. 30%, P < 0.0001). Transdermal rotigotine at doses